🔧На сайте запланированы технические работы
25.12.2025 в промежутке с 18:00 до 21:00 по Московскому времени (GMT+3) на сайте будут проводиться плановые технические работы. Возможны перебои с доступом к сайту. Приносим извинения за временные неудобства. Благодарим за понимание!
🔧Site maintenance is scheduled.
Scheduled maintenance will be performed on the site from 6:00 PM to 9:00 PM Moscow time (GMT+3) on December 25, 2025. Site access may be interrupted. We apologize for the inconvenience. Thank you for your understanding!

 

2,5-Diketopiperazines: A New Class of Poly(ADP-ribose)polymerase Inhibitors


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

We show for the first time that natural 2,5-diketopiperazines (cyclic dipeptides) can suppress the activity of the important anticancer target poly(ADP-ribose)polymerase (PARP). Cyclo(L-Ala-L-Ala) and cyclo(L-Ala-D-Ala) can interact with the key residues of the PARP-1 active site, as demonstrated using docking and molecular dynamics simulations. One of the amide groups of cyclo(L-Ala-L-Ala) and cyclo(L-Ala-D-Ala) forms hydrogen bonds with the Gly863 residue, while the second amide group can form a hydrogen bond with the catalytic residue Glu988, and the side chain can make a hydrophobic contact with Ala898. Newly identified diketopiperazine inhibitors are promising basic structures for the design of more effective inhibitors of PARP family enzymes. The piperazine core with two chiral centers provides many opportunities for structural optimization.

About the authors

D. K. Nilov

Belozersky Institute of Physico-Chemical Biology

Email: vytas@belozersky.msu.ru
Russian Federation, Moscow, 119991

K. I. Yashina

Faculty of Bioengineering and Bioinformatics

Email: vytas@belozersky.msu.ru
Russian Federation, Moscow, 119991

I. V. Gushchina

Faculty of Bioengineering and Bioinformatics

Email: vytas@belozersky.msu.ru
Russian Federation, Moscow, 119991

A. L. Zakharenko

Institute of Chemical Biology and Fundamental Medicine

Email: vytas@belozersky.msu.ru
Russian Federation, Novosibirsk, 630090

M. V. Sukhanova

Institute of Chemical Biology and Fundamental Medicine

Email: vytas@belozersky.msu.ru
Russian Federation, Novosibirsk, 630090

O. I. Lavrik

Institute of Chemical Biology and Fundamental Medicine

Email: vytas@belozersky.msu.ru
Russian Federation, Novosibirsk, 630090

V. K. Švedas

Belozersky Institute of Physico-Chemical Biology; Faculty of Bioengineering and Bioinformatics

Author for correspondence.
Email: vytas@belozersky.msu.ru
Russian Federation, Moscow, 119991; Moscow, 119991

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Pleiades Publishing, Ltd.